Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

ClinicalTrials.gov ID: NCT01877694

Public ClinicalTrials.gov record NCT01877694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.

Study identification

NCT ID: NCT01877694
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: NovaBay Pharmaceuticals, Inc.; Industry
Enrollment: 217 participants

Conditions and interventions

Conditions

Bacterial Conjunctivitis

Interventions

Auriclosene Solution 0.3% Drug
Auriclosene Vehicle Drug

Drug

Eligibility (public fields only)

Age range: 1 Year and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2013 (Type not available)
Primary completion: Dec 2014 (Actual)
Completion: Jan 2015 (Actual)
Last update posted: May 28, 2015

2013 – 2015

United States locations

U.S. sites: 21
U.S. states: 14
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35244	—
Not listed	Phoenix	Arizona	85032	—
Not listed	Anaheim	California	92804	—
Not listed	Bellflower	California	90706	—
Not listed	Glendale	California	91204	—
Not listed	Huntington Beach	California	92647	—
Not listed	Clearwater	Florida	33761	—
Not listed	Woodstock	Georgia	30189	—
Not listed	Evansville	Indiana	47714	—
Not listed	Newton	Kansas	67114	—
Not listed	Whitehouse Station	New Jersey	08889	—
Not listed	Huntersville	North Carolina	28078	—
Not listed	Winston-Salem	North Carolina	27101	—
Not listed	Cincinnati	Ohio	45246	—
Not listed	Dayton	Ohio	45432	—
Not listed	Corsicana	Texas	75110	—
Not listed	San Antonio	Texas	78215	—
Not listed	Clinton	Utah	84015	—
Not listed	Charlottesville	Virginia	22902	—
Not listed	Midlothian	Virginia	23113	—
Not listed	Spokane	Washington	99202	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01877694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 28, 2015 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01877694 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →